Nykredit A S Buys Shares of 506,199 Bristol Myers Squibb Company $BMY

Nykredit A S bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, Holdings Channel.com reports. The institutional investor bought 506,199 shares of the biopharmaceutical company’s stock, valued at approximately $29,167,000.

Several other hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank increased its position in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $405,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $68.06 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company’s fifty day moving average price is $62.73 and its 200-day moving average price is $59.87. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The firm has a market capitalization of $139.03 billion, a PE ratio of 14.99, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging long-term data for Camzyos from the EXPLORER-LTE study supported renewed investor interest in the heart-failure drug. The data add to expectations that Camzyos can remain an important growth product for Bristol Myers Squibb. Bristol Myers Squibb Gains on Camzyos Data
• Positive Sentiment: Analysts and market commentators highlighted bullish technical indicators, strong recent returns, and Bristol Myers Squibb’s outperformance versus the broader healthcare sector. These factors may be attracting momentum-oriented investors. Revisiting Stock Picks
• Neutral Sentiment: RBC Capital maintained a Hold rating, reflecting a balanced view: BMY’s valuation and improving business momentum are constructive, but the stock’s strong run may already incorporate much of the favorable news. RBC Capital Maintains Hold Rating
• Negative Sentiment: Bristol Myers Squibb voluntarily paused enrollment in its zola-cel autoimmune cell-therapy trials after inflammatory side effects emerged during safety monitoring. The pause raises concerns about the therapy’s risk profile, delays a potentially important pipeline program, and may increase scrutiny of trial-disclosure practices. What Does the BMY Trial Pause Mean for Its Pipeline?
• Negative Sentiment: Broader reporting that Novartis and Bristol Myers Squibb halted autoimmune trials following deaths or serious side effects reinforces concerns about the safety and development risk of experimental cell therapies. Drugmakers Halt Autoimmune Trials

Analysts Set New Price Targets

Several brokerages recently weighed in on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Truist Financial reiterated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Cantor Fitzgerald reissued a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.